Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
Public ClinicalTrials.gov record NCT00996658. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Study identification
- NCT ID
- NCT00996658
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 278 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Linagliptin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2009
- Primary completion
- Feb 29, 2012
- Completion
- Not listed
- Last update posted
- Mar 25, 2014
Started 2009
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1218.61.01028 Boehringer Ingelheim Investigational Site | Escondido | California | — | — |
| 1218.61.01014 Boehringer Ingelheim Investigational Site | Greenbrae | California | — | — |
| 1218.61.01015 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1218.61.01042 Boehringer Ingelheim Investigational Site | Paramount | California | — | — |
| 1218.61.01046 Boehringer Ingelheim Investigational Site | Poway | California | — | — |
| 1218.61.01044 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1218.61.01009 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1218.61.01049 Boehringer Ingelheim Investigational Site | Lawrenceville | Georgia | — | — |
| 1218.61.01008 Boehringer Ingelheim Investigational Site | Roswell | Georgia | — | — |
| 1218.61.01040 Boehringer Ingelheim Investigational Site | Meridian | Idaho | — | — |
| 1218.61.01016 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1218.61.01018 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1218.61.01048 Boehringer Ingelheim Investigational Site | Lafayette | Indiana | — | — |
| 1218.61.01001 Boehringer Ingelheim Investigational Site | Auburn | Maine | — | — |
| 1218.61.01043 Boehringer Ingelheim Investigational Site | Olive Branch | Mississippi | — | — |
| 1218.61.01052 Boehringer Ingelheim Investigational Site | Las Vegas | Nevada | — | — |
| 1218.61.01030 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1218.61.01007 Boehringer Ingelheim Investigational Site | Greensboro | North Carolina | — | — |
| 1218.61.01004 Boehringer Ingelheim Investigational Site | Jacksonville | North Carolina | — | — |
| 1218.61.01023 Boehringer Ingelheim Investigational Site | Wilmington | North Carolina | — | — |
| 1218.61.01027 Boehringer Ingelheim Investigational Site | Perrysburg | Ohio | — | — |
| 1218.61.01031 Boehringer Ingelheim Investigational Site | East Providence | Rhode Island | — | — |
| 1218.61.01017 Boehringer Ingelheim Investigational Site | Simpsonville | South Carolina | — | — |
| 1218.61.01005 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1218.61.01006 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1218.61.01053 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1218.61.01003 Boehringer Ingelheim Investigational Site | Sugar Land | Texas | — | — |
| 1218.61.01024 Boehringer Ingelheim Investigational Site | Bennington | Vermont | — | — |
| 1218.61.01020 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00996658, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 25, 2014 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00996658 live on ClinicalTrials.gov.